Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and …

M Guckenberger, Y Lievens, AB Bouma… - The Lancet …, 2020 - thelancet.com
Oligometastatic disease has been proposed as an intermediate state between localised and
systemically metastasised disease. In the absence of randomised phase 3 trials, early …

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

D Planchard, ST Popat, K Kerr, S Novello… - Annals of …, 2018 - annalsofoncology.org
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆

LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial

DA Palma, R Olson, S Harrow, S Gaede… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The oligometastatic paradigm hypothesizes that patients with a limited number of
metastases may achieve long-term disease control, or even cure, if all sites of disease can …

Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial

R Phillips, WY Shi, M Deek, N Radwan, SJ Lim… - JAMA …, 2020 - jamanetwork.com
Importance Complete metastatic ablation of oligometastatic prostate cancer may provide an
alternative to early initiation of androgen deprivation therapy (ADT). Objective To determine …

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer

XS Wang, YF Bai, V Verma, RL Yu… - JNCI: Journal of the …, 2023 - academic.oup.com
Background Adding radiotherapy (RT) to systemic therapy improves progression-free
survival (PFS) and overall survival (OS) in oligometastatic non-small cell lung cancer …

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open …

DA Palma, R Olson, S Harrow, S Gaede, AV Louie… - The Lancet, 2019 - thelancet.com
Background The oligometastatic paradigm suggests that some patients with a limited
number of metastases might be cured if all lesions are eradicated. Evidence from …

Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi …

DR Gomez, C Tang, J Zhang… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Our previously published findings reported that local consolidative therapy (LCT)
with radiotherapy or surgery improved progression-free survival (PFS) and delayed new …

[HTML][HTML] Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document

Y Lievens, M Guckenberger, D Gomez, M Hoyer… - Radiotherapy and …, 2020 - Elsevier
Background Recognizing the rapidly increasing interest and evidence in using metastasis-
directed radiotherapy (MDRT) for oligometastatic disease (OMD), ESTRO and ASTRO …

Contemporary radiotherapy: present and future

RA Chandra, FK Keane, FEM Voncken, CR Thomas - The Lancet, 2021 - thelancet.com
Oncology care is increasingly a multidisciplinary endeavour, and radiation therapy
continues to have a key role across the disease spectrum in nearly every cancer. However …